3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
OTHER
7
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
NET
3
Endocrine
3
Gastrointestinal
2
Sarcoma
1
Lymphoid
1
CNS
1
Conditions
Neuroendocrine Tumors
3
Gastro-enteropancreatic neuroendocrine tumor
2
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Central Nervous System Neoplasms
1
Interventions
Everolimus
15
surufatinib
7
lutetium Lu 177 dotatate
6
lanreotide
6
amino-acid, glucose, and electrolyte solution
5
Octreotide
5
Sunitinib
4
Data Collection
4
pasireotide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
tislelizumab
2
pembrolizumab
2
fosbretabulin
2
arginyllysine
2
Temozolomide
2
Paclitaxel
2
PM 01183
2
Irinotecan
2
Carboplatin
2
64Cu-SARTATE
2
3-Iodobenzylguanidine
2
toripalimab
1
telotristat ethyl
1
taxane
1
repotrectinib
1
pralsetinib
1
pelcitoclax
1
liposomal doxorubicin
1
gadoteridol
1
gadoterate meglumine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neuroendocrine Tumors
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled
NCT03049189
2026-04-06
COMPETE
ITM Solucin GmbH
Phase 3
Active not recruiting
324 enrolled
15 charts
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled